owe
uniqu
function
regul
glucos
lipid
cholesterol
metabol
ppar
peroxisom
proliferatoractiv
receptor
drawn
special
attent
develop
drug
treat
diabet
combin
lipid
benefit
pparalpha
agonist
fibrat
glycem
advantag
ppargamma
agonist
thiazolidinedion
dual
ppar
agonist
approach
improv
metabol
effect
minim
side
effect
caus
either
agent
alon
henc
becom
promis
strategi
design
effect
drug
diabet
studi
mean
power
core
hop
glide
dock
techniqu
novel
class
ppar
dual
agonist
discov
base
compound
wellknown
dual
agonist
pparalpha
ppargamma
modifi
farglitazar
structur
observ
molecular
dynam
simul
novel
agonist
possess
function
activ
pparalpha
ppargamma
also
favor
conform
bind
two
receptor
valid
outcom
adm
absorpt
distribut
metabol
excret
predict
new
agonist
hold
high
potenti
becom
drug
candid
least
find
report
may
stimul
new
strategi
provid
use
insight
discov
effect
dual
agonist
treat
diabet
sinc
core
hop
techniqu
allow
rapidli
screen
novel
core
help
overcom
unwant
properti
gener
new
lead
compound
improv
core
properti
escap
notic
current
strategi
along
correspond
comput
procedur
also
util
find
novel
effect
drug
treat
ill
diabet
mellitu
group
metabol
diseas
classifi
diseas
glucos
overproduct
tissu
without
enough
insulin
product
diseas
result
cell
respond
insulin
human
bodi
diabet
common
type
among
diabet
mellitu
form
risk
develop
diabet
increas
age
obes
cardiovascular
diseas
hypertens
dyslipidaemia
lack
physic
activ
famili
histori
diabet
increas
dramat
us
worldwid
diabet
reach
epidem
scale
nearli
million
individu
us
million
individu
worldwid
metabol
syndrom
peopl
suffer
overweight
obes
huge
risk
develop
peroxisom
proliferatoractiv
receptor
ppar
drawn
increas
attent
drug
discoveri
target
regul
glucos
lipid
metabol
ppar
subtyp
ppara
pparc
belong
superfamili
nuclear
receptor
function
transcript
factor
activ
sever
ligand
ppar
play
vital
import
role
treat
obes
atherogen
dyslipidemia
hypertens
insulin
resist
main
therapeut
target
primari
function
ppara
act
regul
respond
transport
degrad
free
fatti
acid
well
revers
cholesterol
transport
peroxisom
betaoxid
pathway
class
lipidlow
drug
fenofibr
gemfibrozil
special
activ
ppara
pparc
play
signific
role
transcript
regul
lot
physiolog
pathway
includ
adipocyt
differenti
glucos
homeostasi
thiazolidinedion
tzd
class
antidiabet
drug
act
activ
special
pparc
use
alon
although
antidiabet
drug
could
enhanc
insulin
sensit
henc
lower
glucos
fatti
acid
level
diabet
patient
side
effect
would
caus
weight
gain
fluid
accumul
pulmonari
edema
recent
new
dual
agonist
receiv
consider
attent
develop
power
drug
diabet
strategi
dual
agonist
aim
treat
insulin
resist
dyslipidemia
critic
challeng
develop
dual
agonist
identifi
receptor
subtyp
select
ratio
mani
studi
indic
comput
approach
structur
bioinformat
molecular
dock
pharmacophor
model
qsar
techniqu
well
seri
userfriendli
webserv
predictor
develop
recent
identifi
g
proteincoupl
receptor
type
enzclasspr
predict
enzym
class
iloceuk
ilochum
predict
subcellular
local
eukaryot
human
protein
inrphyschem
identifi
nuclear
receptor
subfamili
hivcleav
predict
hiv
proteas
cleavag
site
protein
time
provid
use
inform
insight
drug
develop
softwar
core
hop
anoth
power
cuttingedg
comput
techniqu
particularli
use
de
novel
drug
design
encourag
aforement
research
success
util
variou
comput
approach
drug
develop
present
studi
initi
attempt
screen
fragment
databas
find
new
ppar
dual
agonist
treat
diabet
realiz
techniqu
core
hop
glide
dock
well
molecular
dynam
simul
util
analyz
bind
interact
agonist
ppar
hope
find
thu
obtain
may
provid
use
insight
develop
new
power
agonist
diabet
mellitu
ltyrosin
analogu
obtain
modifi
structur
farglitazar
dual
agonist
ppara
pparc
main
differ
farglitazar
former
contain
vinylog
amid
ltyrosin
nsubstitu
chose
start
templat
structur
design
new
ppar
dual
agonist
repres
complex
crystal
structur
ppara
pdb
id
pparc
pdb
id
ligand
download
pdb
bank
use
molecular
model
studi
calcul
carri
dell
precis
tm
comput
schroding
softwar
packag
desmond
protein
pdb
code
chosen
model
addit
avail
knowledg
dimension
structur
reason
select
two
protein
receptor
follow
two
protein
contain
ligand
ppara
pparc
bind
affin
ligand
also
quit
similar
howev
former
select
weaker
latter
sourc
organ
ppara
pparc
human
process
prepar
receptor
model
protein
prepar
facil
use
includ
oper
assign
bond
order
ad
hydrogen
treat
metal
treat
disulfid
delet
water
allevi
potenti
steric
clash
adjust
bond
order
build
miss
heavi
atom
formal
charg
well
minim
energi
forc
field
refin
protein
impos
rmsd
limit
constraint
protein
bindingsit
identifi
sitemap
tool
embed
schroding
suit
wwwschrodingercom
describ
bindingsit
encompass
ligand
observ
crystal
structur
ppara
pparc
ligand
inform
bind
pocket
receptor
ligand
import
drug
design
particularli
conduct
mutagenesi
studi
literatur
bind
pocket
protein
receptor
ligand
usual
defin
residu
least
one
heavi
atom
ie
atom
hydrogen
distanc
heavi
atom
ligand
criterion
origin
use
defin
bind
pocket
atp
complex
later
prove
quit
use
identifi
function
domain
stimul
relev
truncat
experi
similar
approach
also
use
defin
bind
pocket
mani
receptorligand
interact
import
drug
design
studi
also
use
criterion
defin
bind
pocket
protein
ligand
closeup
view
proteinligand
interact
bind
pocket
thu
defin
shown
fig
panel
interact
ppara
panel
b
interact
pparc
natur
ligand
ppar
fatti
acid
bind
site
ppar
almost
hydrophob
sever
hydrophob
interact
three
arm
yshape
ligand
bind
site
taken
key
point
design
new
ppar
agonist
ppar
bind
site
compos
three
arm
name
arm
arm
ii
arm
iii
explicitli
mark
fig
first
arm
mainli
polar
charact
includ
transcript
activ
function
helix
indic
red
ribbon
hydrophil
head
group
ppar
ligand
form
network
hydrogen
bond
armi
hydrophob
tail
ppar
agonist
either
interact
arm
ii
arm
iii
network
hydrogen
bond
form
import
conform
gener
charg
clamp
thu
reduc
mobil
via
bind
ligand
henc
make
abl
regul
gene
express
druglik
databas
fragment
databas
deriv
zinc
use
virtual
screen
core
hop
search
respect
mani
use
insight
drug
design
could
gain
via
molecular
dock
studi
see
eg
acquir
even
use
inform
drug
design
new
dock
algorithm
call
core
hop
adopt
studi
featur
function
perform
fragmentbas
replac
molecular
dock
core
hop
power
cuttingedg
techniqu
de
novel
drug
design
significantli
improv
bind
affin
receptor
ligand
eg
fig
current
studi
bind
conform
thu
obtain
taken
initi
structur
optim
search
fragment
databas
find
optim
core
attach
part
templat
process
core
hop
step
defin
possibl
point
core
attach
perform
defin
combin
step
combinatori
screen
panel
wwwschrodingercom
step
defin
receptor
grid
file
done
receptor
prepar
panel
step
core
prepar
oper
protocor
prepar
modul
find
core
attach
scaffold
use
fragment
databas
deriv
zinc
step
align
dock
entir
molecular
structur
built
core
scaffold
core
sort
filter
good
align
redock
receptor
attach
scaffold
follow
use
dock
score
sort
final
molecul
product
core
hop
oper
total
chemic
compound
prepar
ligpr
modul
consist
procedur
gener
possibl
state
ioniz
target
ph
desalt
retain
chiral
structur
geometri
minim
forc
field
step
accomplish
investig
compound
dock
receptor
pocket
rigid
protein
dock
model
standprecis
sp
score
function
estim
bind
affin
mani
marvel
biolog
function
protein
dna
well
profound
dynam
mechan
switch
activ
inact
state
cooper
effect
alloster
transit
intercal
drug
dna
assembl
microtubul
reveal
studi
intern
motion
likewis
realli
understand
interact
mechan
receptor
ligand
investig
aim
static
structur
also
dynam
process
obtain
simul
intern
motion
desmond
packag
adopt
studi
intern
motion
receptorligand
system
accord
softwar
opl
forc
field
use
build
aqueou
biolog
system
model
use
simul
water
molecul
orthorhomb
period
boundari
condit
set
specifi
shape
size
repeat
unit
order
get
electr
neutral
system
minimum
number
sodium
chlorid
ion
need
balanc
system
charg
place
randomli
solvat
system
moll
sodium
chlorid
ad
mimic
osmot
effect
water
molecular
dynam
simul
carri
period
boundari
condit
npt
ensembl
temperatur
pressur
kept
k
atmospher
pressur
use
nosehoov
temperatur
coupl
isotrop
scale
restrain
remov
via
nanosecond
second
system
minim
relax
oper
follow
run
ns
npt
product
simul
save
configur
thu
obtain
picosecond
second
interv
molecular
dynam
simul
perform
time
step
femtosecond
second
qikprop
program
predict
adm
absorpt
distribut
metabol
excret
properti
compound
qikprop
softwar
total
properti
compound
predict
includ
princip
descriptor
physiochem
properti
compound
investig
need
treatment
neutral
use
qikprop
automat
done
qikprop
normal
mode
appli
program
properti
analys
partit
coeffici
qp
logp
ow
van
der
waal
surfac
area
polar
nitrogen
oxygen
atom
psa
predict
aqueou
solubl
qp
log
b
appar
mdck
permeabl
qpp
mdck
c
consid
qikpro
evalu
accept
compound
process
core
hop
final
agonist
structur
thu
select
illustr
fig
see
follow
structur
conceiv
agonist
model
develop
novel
therapeut
agent
treat
metabol
disord
may
divid
three
part
core
core
b
core
c
mark
dash
line
consid
great
import
acid
head
core
activ
ppar
receptor
let
us
retain
core
part
core
hop
calcul
describ
core
hop
oper
aim
core
c
part
see
red
part
fig
gener
five
core
core
core
core
core
core
respect
replac
core
c
core
hop
oper
aim
core
b
part
see
bind
pocket
defin
residu
least
one
heavi
atom
distanc
ligand
ligand
grey
color
extract
crystal
structur
ligand
comp
render
three
color
grey
core
red
core
b
blue
core
c
gener
corehop
method
hydrophob
surfac
receptor
color
green
blue
part
fig
also
respect
gener
five
core
core
core
core
core
core
replac
core
b
consequ
total
differ
combin
deriv
thu
gener
subsequ
deriv
compound
dock
two
receptor
ppara
pparc
respect
list
tabl
deriv
compound
rank
roughli
accord
dock
score
receptor
ppara
pparc
respect
top
ten
compound
highlight
boldfac
type
tabl
deriv
stronger
origin
bind
affin
two
receptor
top
ten
deriv
comp
ie
core
acor
strongest
bind
affin
ppara
pparc
henc
singl
investig
shown
fig
dock
conform
comp
align
extract
crystal
complex
ppara
b
crystal
complex
pparc
respect
describ
convers
hbond
network
form
polar
acid
head
core
comp
four
key
residu
ppara
pparc
observ
dock
studi
hbond
network
play
role
stabil
conform
arm
red
helix
fig
vital
import
receptorbind
activ
hydrophob
tail
core
core
c
agonist
buri
well
hydrophob
arm
arm
ii
form
hydrophob
residu
shown
green
surfac
fig
compar
shown
grey
color
fig
compound
comp
purpl
color
fig
bulki
molecular
volum
owe
larg
hydrophob
core
fit
hydrophob
arm
ii
result
much
better
bind
affin
cf
tabl
molecular
dynam
provid
use
inform
character
intern
motion
biomacromolecul
time
comparison
studi
ns
molecular
dynam
simul
perform
respect
crystal
structur
ppara
pparc
well
complex
comp
ie
pparacomp
pparccomp
see
fig
charact
concern
reach
simul
equilibrium
within
see
panel
c
meanwhil
correspond
root
mean
squar
deviat
rmsd
valu
curv
protein
backbon
ppara
pparc
pparacomp
pparccomp
also
comput
respect
interest
see
rmsd
curv
pparacomp
pparccomp
remark
stabl
particularli
case
ppara
system
fluctuat
around
nm
observ
complex
system
reach
plateau
detail
fluctuat
aforement
six
differ
structur
well
root
mean
squar
fluctuat
rmsf
sidechain
atom
also
comput
within
ns
molecular
dynam
simul
see
panel
b
fig
instruct
point
rmsf
curv
pparacomp
pparccomp
highli
similar
respect
especi
remark
bind
site
helix
region
residu
pparacomp
residu
pparccomp
see
grey
frame
fig
indic
new
design
compound
comp
like
function
activ
helix
done
neg
control
similar
molecular
dynam
simul
also
perform
comp
rank
number
accord
strength
bind
affin
ppara
pparc
cf
tabl
correspond
simul
result
thu
obtain
shown
fig
see
fluctuat
magnitud
molecular
dynam
pparacomp
pparccomp
includ
rmsd
rmsf
much
larger
pparacomp
pparccomp
especi
bind
site
helix
region
see
gray
frame
fig
phenomena
indic
comp
good
comp
stabli
bind
ppara
pparc
henc
comp
might
function
activ
helix
pharmaceut
relev
properti
new
design
agonist
deriv
well
origin
compound
partit
coeffici
logpow
van
der
waal
surfac
area
polar
nitrogen
oxygen
atom
psa
aqueou
solubl
log
appar
mdck
permeabl
pmdck
predict
mean
qp
program
embed
softwar
packag
result
thu
obtain
also
list
tabl
respect
sinc
ppara
pparc
spaciou
pocket
nuclear
hormon
receptor
quit
natur
agonist
deriv
design
base
two
receptor
combin
three
core
would
rel
larg
molecular
weight
bulki
volum
trend
quit
similar
case
design
inhibitor
protein
tyrosin
phosphat
ptpase
shown
tabl
valu
calcul
qp
program
pa
logpow
log
pmdck
newli
design
agonist
within
reason
rang
although
higher
logpow
valu
compound
stronger
affin
ppar
good
idea
excess
enhanc
logpow
would
induc
bad
distribut
compound
fat
bodi
fluid
point
rather
experienti
valu
within
rang
log
valu
new
agonist
quit
close
phenomenon
might
result
core
part
kept
unchang
process
design
newli
compound
mention
core
part
modifi
well
log
valu
would
improv
accordingli
also
mention
valu
four
adm
properti
list
tabl
within
accept
rang
human
be
indic
compound
particularli
top
deriv
found
studi
highlight
tabl
util
candid
purpos
develop
new
drug
goal
studi
find
new
power
dual
agonist
ppara
pparc
new
techniqu
core
hop
adopt
studi
allow
rapid
screen
novel
core
help
overcom
unwant
properti
gener
new
lead
compound
improv
core
properti
set
novel
compound
found
regard
compar
exist
dual
agonist
new
agonist
similar
function
activ
ppara
pparc
also
assum
conform
favor
bind
ppara
pparc
anticip
new
agonist
may
becom
potenti
drug
candid
least
may
stimul
new
strategi
develop
novel
dual
agonist
diabet
